Contents
Download PDF
pdf Download XML
511 Views
130 Downloads
Share this article
Research Article | Volume 13 Issue:4 (, 2023) | Pages 988 - 996
Comparative Study of Oral Single Dose Fluconazole 150mg with Intravaginal Sertaconazole 500mg in the Treatment of Vulvovaginal Candidiasis
Under a Creative Commons license
Open Access
Received
Sept. 26, 2023
Revised
Oct. 12, 2023
Accepted
Nov. 5, 2023
Published
Nov. 30, 2023
Abstract

Introduction: Vulvovaginal candidiasis (VVC) is a common cause of vaginal discharge in women of reproductive age-group.It affects 75% of women at least once during their lifetime and 10% of them have recurrent episodes.Most common offending organism is Candida albicans, and Candida glabrata being the most common non albicans species.Based on clinical presentation, microbiology, host factor like immunosuppression and recurrence, VVC is classified into complicated and uncomplicated VVC. The treatment of VVC is reasonably effective with a range of oral and intravaginal agents with Azoles being the predominant antifungals used. Aim And Objective: To compare the safety and efficacy of oral tablet fluconazole 150 mg single dose with intravaginal sertaconazole 500mg in the treatment of vulvovaginal candidiasis. MATERIALS AND METHODS: After obtaining informed consent, 100 patients who were clinically and mycologically confirmed to have vulvovaginal candidiasis were included in the study. They were randomly assigned into 2 groups, containing 50 patients each. Group A was treated with single dose of oral tablet fluconazole 150mg and group B was treated with sertaconazole 500mg vaginal pessary.The patients were reviewed at day 7 and 14 after the treatment. At each visit, symptomatic and mycological improvements were assessed and recorded. Results: A total of 97 patients completed the study.The symptomatic cure rate in both the groups at day 7 was 64.58% and 81.63% and in day 14 was 95.8% and 91.8% respectively in each group.The mycological cure rate in both groups at day 7 was 54.1%and 65.3% and day 14 was 75.1% and 85.7% respectively.  Conclusion: Treatment of VVC with single dose Sertaconazole 500mg vaginal pessary results in rapid symptom clearance and lesser recurrence rate than oral Fluconazole 150mg tablet in the treatment of uncomplicated VVC, in women with personal preference of vaginal route of drug administration without significant drug interactions and adverse effects. This can also be beneficial in the era of emerging fluconazole resistance.

Keywords
Recommended Articles
Research Article
Study Of Hematological Abnormalities in Decompensated Chronic Liver Disease
...
Published: 30/06/2025
Download PDF
Research Article
Role of Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in prediction of clinical outcomes in patients with acute coronary syndrome
...
Published: 30/09/2025
Download PDF
Research Article
Comparison of Intravenous Magnesium Sulphate and Clonidine in Attenuating Hemodynamic Responses during Laryngoscopy and Tracheal Intubation: A Prospective Randomized Double-Blind Study
Published: 30/09/2020
Download PDF
Research Article
A Study Comparing Pre- Operative Prophylactic Iv Antibiotics with Combined IV and Intraincisional Antibiotics Administration for Reducing Surgical Site Infections
...
Published: 27/09/2025
Download PDF
Chat on WhatsApp
Copyright © EJCM Publisher. All Rights Reserved.